Urinary Incontinence — Symptoms, Causes & Treatment | MyMedicPlus

Urinary incontinence (UI) is the involuntary leakage of urine — any amount — at any inappropriate time or place. It is one of the most prevalent yet underreported conditions, affecting approximately 20-30% of women, 10-20% of men, and over 50% of nursing home residents. Despite its prevalence, fewer than half of affected individuals seek medical help due to embarrassment, mistaken belief that incontinence is a normal or inevitable aspect of ageing (it is not — it is treatable), or a lack of awareness that effective treatments exist. UI is classified into five main types: stress urinary incontinence (SUI) — leakage during physical effort, coughing, sneezing, or exercise, caused by failure of urethral closure mechanisms; urgency urinary incontinence (UUI) — leakage preceded by a sudden, compelling urge to void, caused by overactive detrusor (bladder wall) muscle contractions; mixed urinary incontinence — both SUI and UUI components (the most common type in women); overflow incontinence — involuntary leakage from an overdistended bladder that fails to empty (associated with bladder outlet obstruction or detrusor underactivity); and functional incontinence — inability to reach the toilet in time due to physical or cognitive impairment despite a normally functioning bladder. The social and psychological impact is profound — UI causes social withdrawal, reduced sexual activity, depression, anxiety, and workplace impairment. The annual healthcare cost of UI in the UK exceeds £530 million.

Stress urinary incontinence (SUI): pelvic floor muscle weakness and urethral hypermobility from pregnancy and vaginal childbirth — particularly prolonged second-stage labour, instrumental delivery (forceps or ventouse), high birth-weight infants, and multiple deliveries, all of which damage the levator ani muscles and pudendal nerve innervation; menopause (oestrogen deficiency causes urethral mucosal atrophy and reduced coaptation pressure — 40-50% of postmenopausal women experience SUI); obesity (BMI above 30 chronically elevates intra-abdominal pressure and doubles or triples SUI risk — 10% weight loss reduces SUI episodes by 50%); chronic cough from COPD or smoking-induced bronchitis; and prior pelvic surgery or radiotherapy (disrupts fascial urethral support mechanisms). Urgency urinary incontinence (UUI) and overactive bladder (OAB): detrusor overactivity (idiopathic — most common; neurogenic — suprapontine lesions from stroke, Parkinson's disease, multiple sclerosis; spinal cord injury causing detrusor-sphincter dyssynergia); lower urinary tract infection (inflamed bladder mucosa lowers sensory threshold, producing urgency; UTI-associated urgency is fully reversible with antibiotic treatment); bladder calculi; bladder cancer (haematuria plus urgency warrants cystoscopy to exclude malignancy). Overflow incontinence: bladder outlet obstruction from benign prostatic hyperplasia in men, urethral stricture, or pelvic organ prolapse; and detrusor underactivity from diabetic autonomic neuropathy (impairs bladder contractility leading to chronic retention and overflow). Medications contributing to incontinence: diuretics (furosemide, thiazides — cause polyuria and urgency incontinence); alpha-adrenergic blockers (tamsulosin — relaxes internal urethral sphincter smooth muscle causing SUI in women); anticholinergics (cause urinary retention and overflow by impairing detrusor contractility).

SUI: involuntary leakage with physical effort (cough, sneeze, laugh, exercise, standing from chair). UUI: sudden strong urge to void followed by involuntary leakage before reaching toilet. Mixed UI: both SUI and UUI symptoms. Overflow UI: continuous dribbling or frequent small-volume leakage from an overdistended bladder. Nocturia (waking ≥2 times to void) is associated with UUI and OAB. Use of pads quantifies severity. Symptom severity varies significantly between affected individuals and fluctuates over time in the same person, influenced by treatment adherence, lifestyle factors, comorbidities, and disease stage. Prompt clinical recognition of symptom worsening and early self-reporting to a healthcare provider can prevent progression to more severe disease stages, reduce the risk of complications, and improve the likelihood of achieving and maintaining disease control.

Bladder diary (3-day frequency-volume chart): the most important initial investigation — the patient records every void (time, volume estimated by measuring in a jug), urgency episodes, and leakage events over 3 days; identifies type (SUI pattern vs. UUI urgency-leak episodes), daily voided volumes, frequency, and whether nocturia is from true detrusor overactivity or excessive fluid intake. Symptom questionnaire: ICIQ-UI Short Form (3-item validated questionnaire) quantifies severity and impact. Physical examination: abdominal examination for palpable bladder (overflow); pelvic examination in women — assess pelvic organ prolapse (anterior, posterior, or apical compartment), pelvic floor muscle tone, and perineal sensation; rectal examination in men — prostate size and regularity (BPH); neurological examination (lower limb reflexes, perineal sensation — cauda equina or cord lesion). Cough stress test: patient with full bladder is asked to cough forcefully — immediate synchronous leakage confirms SUI. Post-void residual (PVR) bladder ultrasound: PVR above 100-150 mL suggests voiding dysfunction or overflow incontinence; above 300 mL indicates significant chronic retention. Urinalysis and MSU culture: exclude UTI (which causes or exacerbates UUI) and haematuria (which requires cystoscopy to exclude bladder cancer). Urodynamics (multichannel filling cystometry plus pressure-flow voiding study): measures intravesical and intraabdominal pressure simultaneously during bladder filling and voiding; defines urodynamic stress incontinence (involuntary leakage at raised intra-abdominal pressure on cystometry) vs. detrusor overactivity (involuntary detrusor contractions during filling); recommended before all surgical procedures and in complex cases. Cystoscopy: for haematuria, suspected interstitial cystitis, or suspected intravesical pathology (stones, tumour).

Conservative first-line interventions for all types: pelvic floor muscle training (PFMT — Kegel exercises: squeeze and lift the pelvic floor for 6-8 seconds, 3 sets of 8-12 contractions daily for at least 12 weeks; a properly supervised programme with a pelvic floor physiotherapist achieves 60-70% significant improvement or cure in SUI; biofeedback, electrical stimulation, and vaginal cones augment PFMT); bladder training for UUI/OAB (urge suppression techniques — distract, stand still, contract pelvic floor — to defer voiding and extend intervals between voids progressively by 15-minute increments over 6-12 weeks; reduces incontinence episodes by 60%); fluid management (1.5-2 litres per day — neither excessive restriction nor overdrinking; caffeine restriction: caffeine is a diuretic and bladder irritant — reducing to below 2 cups daily significantly improves OAB symptoms); weight management (10% weight loss reduces SUI episodes by 50%). Pharmacotherapy for SUI: duloxetine 40 mg twice daily — a serotonin-norepinephrine reuptake inhibitor that increases urethral sphincter tone through pudendal nerve motor neurons; reduces SUI episodes by 50% in trials but is second-line due to side effects (nausea, insomnia, dizziness) and is not licensed in the US for this indication. Pharmacotherapy for UUI/OAB: antimuscarinics (solifenacin 5-10 mg, oxybutynin 5 mg, tolterodine 4 mg, fesoterodine — reduce detrusor overactivity; caution in elderly due to cognitive impairment and falls risk); mirabegron (beta-3 adrenoceptor agonist 50 mg daily — equally effective to antimuscarinics, fewer anticholinergic side effects, and preferred in elderly; raises blood pressure modestly — monitor); combination mirabegron plus solifenacin (SYNERGY trial — superior to either alone). Intravesical botulinum toxin A (onabotulinumtoxinA 100 units — cystoscopic injection into the detrusor; 60-70% reduction in UUI episodes; duration 6-9 months then repeat; risk of urinary retention requiring self-catheterisation in 5-10%). Sacral neuromodulation (SNS — InterStim — implanted sacral nerve stimulator modulates the micturition reflex; for refractory OAB not responding to medication — 70-80% success). Surgery for SUI: mid-urethral polypropylene tape (TVT — retropubic; TOT — transobturator) — the gold standard surgical treatment with 80-90% long-term cure; performed under local or general anaesthesia; risk of voiding dysfunction and mesh complications (erosion into bladder or vagina — rare). Colposuspension (Burch) — open or laparoscopic alternative with comparable efficacy. Autologous fascial pubovaginal sling: preferred in patients requiring primary or secondary surgery to avoid synthetic mesh.

Perineal dermatitis and pressure sores (continuous moisture). Recurrent urinary tract infections. Falls and fall-related injuries (rushing to toilet for urgency UI). Sleep disruption (nocturia and urgency). Social isolation, depression, anxiety, reduced sexual function, and significant impairment in quality of life. Overflow incontinence risks hydronephrosis, recurrent UTIs, and progressive renal impairment if untreated. Long-term specialist follow-up and structured regular review are essential to detect and appropriately manage complications at the earliest possible stage, minimising long-term disability, preserving organ function, and improving the overall prognosis. Patient education about the early warning signs of complications and clear guidance on when to seek urgent medical attention empowers timely help-seeking behaviour and reduces preventable serious adverse outcomes. Psychological impact — including depression, anxiety, and reduced quality of life — should be proactively assessed and addressed as part of comprehensive complication management.

Maintain healthy BMI (obesity is the strongest modifiable risk factor — 10% weight loss reduces SUI by 50%). Antenatal and postnatal PFMT reduces postpartum UI. Treat chronic constipation. Quit smoking (cough-induced SUI). Limit caffeine to <200 mg/day. Supervised PFMT with specialist continence nurse or physiotherapist before surgical referral. Postmenopausal vaginal estrogen cream reduces UUI and recurrent UTI. Sustained lifestyle modifications — maintaining a healthy body weight through balanced diet and regular physical activity, avoiding tobacco smoking, limiting alcohol intake, and managing chronic conditions such as hypertension and diabetes — are foundational strategies for reducing the risk of this condition and its complications. Regular health screening in at-risk populations, rigorous adherence to prescribed preventive medications, and proactive monitoring of established risk factors are equally critical and complementary components of a comprehensive and effective long-term prevention strategy.

See a GP or continence nurse for any urinary leakage that affects your quality of life, social activities, or daily routine — incontinence is extremely common and underreported due to embarrassment, but is very treatable. There is no need to accept it as inevitable with ageing. A bladder diary and examination can identify the type (stress, urgency, or mixed) and direct treatment. Seek urgent medical assessment for: sudden new onset urinary incontinence in a previously continent person — particularly with back pain, leg weakness, or numbness (possible cauda equina syndrome — spinal emergency requiring same-day MRI and neurosurgical review); haematuria (blood in urine) associated with incontinence (bladder cancer must be excluded); painful incontinence with fever and loin pain (pyelonephritis or urosepsis); and inability to pass urine (acute urinary retention) with overflow incontinence. Seek urology or urogynecology referral for: incontinence not responding to 12 weeks of supervised PFMT and bladder training; recurrent urinary infections with incontinence; symptoms of pelvic organ prolapse; and when surgery (TVT, sacral neuromodulation, or botulinum toxin) is being considered.